Lumos Pharma Announces Governance Decisions and Trial Updates
Company Announcements

Lumos Pharma Announces Governance Decisions and Trial Updates

Lumos Pharma (LUMO) has shared an update.

At Lumos Pharma’s 2024 Annual Meeting, shareholders elected directors Chad A. Johnson and Lota S. Zoth, approved the executive compensation on an advisory basis, decided on annual advisory votes for future executive compensation, and ratified KPMG, LLP as the independent auditor for the fiscal year. The company also announced new analyses from the Phase 2 OraGrowtH212 trial at ENDO 2024, details of which were shared in a press release and an updated corporate slide deck. These updates highlight the company’s ongoing commitment to transparency and shareholder engagement in its governance and operational progress.

See more insights into LUMO stock on TipRanks’ Stock Analysis page.

Related Articles
Austin AngeloLUMO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
TipRanks Auto-Generated NewsdeskLumos Pharma Faces Uncertainty as CVRs Risk Expiring Worthless Post-Merger
TheFlyLumos Pharma downgraded to Neutral from Buy at H.C. Wainwright
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App